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a b s t r a c t
Imaging in coronary artery disease should be regarded as a tool supporting patients'
management. Imaging helps physicians to diagnose patients more precisely and to treat
them more effectively. There is a constant need to improve the decision-making process in
patients with coronary artery disease. The growing number of cardiac magnetic resonance
(CMR) centres, patients undergoing CMR studies and the plethora of evidence for the use of
CMR both in patients with stable coronary artery disease, as well as acute coronary
syndromes, justify reviewing its capabilities. Although research applications and technical
developments are of particular value for progress being made in the ﬁeld of imaging, clinical
applications are the most crucial for patients and treating physicians, thus they will be
discussed.
# 2015 The Czech Society of Cardiology. Published by Elsevier Sp. z o.o. All rights
reserved.
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Imaging in coronary artery disease (CAD) should be regarded
as a tool supporting patients' management. Imaging helps
physicians to diagnose patients more precisely and to treat
them more effectively. Although in many cases the diagnosis
or the exclusion of stable CAD can be made on the basis of
clinical evaluation including patients' age, sex and chest pain
characteristics, in numerous patients the tool verifying the
baseline clinical judgement is needed. Moreover, a physician
needs information additional to clinical evaluation to make a
decision about management strategy (conservative vs invasive
treatment, percutaneous vs surgical treatment, etc.) [1,2].
In the case of acute coronary syndromes (ACS), in the vast
majority of cases, there is no need (and no sense) to perform
imaging test additional to clinical evaluation and ECG to
conﬁrm that the patient really has ACS [3,4]. Particularly, in
patients with ST-segment elevation myocardial infarction
(STEMI) coronary angiography should be performed without
any delay [4]. Invasive imaging (coronary angiography) is
crucial for patients' treatment, and non-invasive imaging is
indispensable for determining complications, further treat-
ment needs and options as well as patients' prognosis.
There is a constant need to improve the decision-making
process in these situations. Among other imaging modalities,
cardiac magnetic resonance (CMR) is being more and more
commonly used not only in research projects, but also in
normal clinical scenarios. The growing number of CMR
centres, patients undergoing CMR studies and the plethora
of evidence for the use of CMR both in patients with stable
CAD, as well as ACS justify reviewing its capabilities [5].
Although research applications and technical developments
are of particular value for progress being made in the ﬁeld of
imaging, clinical applications are the most crucial for patients
and treating physicians, thus they will be discussed.
Stable coronary artery disease
The main questions that a physician treating a patient with
suspected CAD needs to answer include the following [1,2]:
- Does a patient have CAD?
- Should a patient undergo revascularisation?
- Should a patient undergo percutaneous (percutaneous
coronary intervention – PCI) or surgical treatment (coronary
artery bypass grafting – CABG)?
- Is there any additional disease that should be treated
simultaneously (valvular disease, dilated aorta)?
- If not CAD, what could be the cause of chest pain?
When we review diagnostic capabilities of each imaging
modality, one should think whether it could answer thesequestions. Does CMR answer these questions? It does! (. . . well
almost).
Does the patient have CAD?
CMR has emerged as a valuable tool in the assessment of
patients with suspected CAD. The growing evidence support-
ing the use of CMR to diagnose the presence of CAD has led to
the recognition of stress CMR as a method equal to well
established methods of functional testing in the case of
suspected CAD, namely stress echocardiography, nuclear
imaging (single photon emission computed tomography –
SPECT), and positron emission tomography (PET) perfusion
[1,2]. But the very ﬁrst imaging modality in patients with
suspected CAD should be transthoracic echocardiography and
determining left ventricular ejection fraction (LVEF) [1]. This
guides further management:
(A) Patients with typical angina and impaired LVEF (<50%)
should undergo invasive coronary angiography without
delay related to additional test. Except for patients with
poor acoustic window, in whom echocardiography is not
able to provide reliable data on LVEF, there is no room for
CMR at this initial diagnostic step in these patients.
However, CMR (or other stress imaging test) may be
needed after coronary angiography to assess the extent of
ischaemia and/or myocardial viability.
(B) In patients with LVEF <50% without typical angina,
imaging stress test should be the initial test for diagnosing
CAD.
(C) In the remaining patients (i.e. those with LVEF ≥50%), a
physician should determine pre-test probability of CAD.
Stress testing for ischaemia is needed in patients with
intermediate pre-test probability of the disease. Alterna-
tively, anatomical detection of CAD with the use of
computed tomography (CT) angiography may be applied
in selected patients.
Stress CMR offers several stress agents and protocols that
are similar to those used in nuclear imaging (vasodilators:
adenosine, dipyridamole or regadenoson) or stress echocardi-
ography (dobutamine-atropine protocol) [6–8]. Details in
protocols as well as pharmacological agents used in stress
CMR may vary between CMR centres.
Should the patient undergo revascularisation?
Perfusion defects or new wall motion abnormalities during
stress testing conﬁrm the diagnosis of stable CAD. This is,
however, not enough to make a decision regarding revascu-
larisation. Current guidelines for revascularisation require
evidence that the extent of ischaemia is signiﬁcant, since only
in this group of patients revascularisation improves prognosis
in terms of CAD and all-cause mortality [1,2]. The huge
Fig. 1 – Stress perfusion cardiac magnetic resonance in three slices (left to right: basal, mid-ventricular, apical). (A) Large
perfusion defect consistent with moderate–severe ischaemia is seen in the territory supplied by the right coronary artery
(arrows). (B) Smaller perfusion defect seen in a different patient (arrows).
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stable CAD is the fact that simultaneously with the diagnosis
of CAD, we receive the information concerning the extent of
ischaemia (Fig. 1). This is a common advantage of imaging
stress tests that is lacking in the case of ECG exercise test,
coronary angiography or coronary CT angiography [1,2].
Although various imaging stress tests are able to provide
the information on the extent of ischaemia, the deﬁnition of
signiﬁcant ischaemia varies between them [1,9,10]. Since there
are no studies with the use of CMR determining the ischaemia
burden threshold in terms of improved survival after revas-
cularisation, the ﬁndings from stress nuclear imaging are
interpolated in this ﬁeld [9,10]. The question is, how to
translate area of ischaemia ≥10% of the left ventricular
myocardium in SPECT into CMR perfusion or dobutamine
study. According to the European Society of Cardiology
guidelines, high risk in CMR ischaemia imaging means ≥2
out of 16 segments of the left ventricle being ischaemic on
stress perfusion or ≥3 segments of the left ventricle with
dysfunction induced by dobutamine stress test [1]. This
deﬁnition, however, is not based on randomised controlled
trials. The precise answer to the questions what is a signiﬁcant
burden of ischaemia in CMR perfusion studies and who
beneﬁts from revascularisation will be provided by two
ongoing studies. The MR-INFORM study compares two strate-
gies in patients with suspected CAD [10]. In one arm, the
decisions about the need for revascularisation are guided by
invasive fractional ﬂow reserve. In the second arm, CMR
perfusion-guided therapy is implemented. In patients in CMRarm, angiography (with intention to revascularise) is recom-
mended in the case of perfusion defects in at least 2 segments
of a 32-segment model. A 32-segment model means that each
segment of a 16-segment model was divided into two halves:
an endocardial and an epicardial one [10]. In the ISCHEMIA
trial, the criteria for moderate–severe ischaemia mean ≥4 of 32
subsegments with perfusion defects [9]. In a 32 segment
model, each subsegment equals to approximately 3% of the
myocardium, so 2 subsegments represent 6% of the myocar-
dium, and 4 subsegments – 12%, respectively. Both thresholds
are near to SPECT-derived 10% threshold. The future will show
which criterion is more accurate for patients' management.
The next important question, next to ischaemia testing,
which needs to be solved prior to revascularisation is
myocardial viability [2,11]. Although, the substudy of the
STICH trial raised concerns about the impact of viability
assessment on the outcomes after revascularisation, still
viability needs to be taken into consideration when revascu-
larisation in patients with heart failure due to ischaemic
aetiology is planned [2,11–13]. CMR offers a simple and robust
analysis of myocardial viability. It is based on prolonged wash
out of gadolinium contrast agents from necrotic or ﬁbrotic
tissue, causing the phenomenon of late gadolinium enhance-
ment (LGE) in these areas [14,15]. In the landmark study, Kim
et al. showed that the transmural extent of LGE (expressed in
percentages of the left ventricular wall thickness) corresponds
to the likelihood of function recovery after revascularisation
[14]. The greater extent of LGE is associated with a lower
likelihood of improving contractility after PCI or CABG (Fig. 2).
Fig. 2 – Viability imaging in cardiac magnetic resonance with the use of late gadolinium enhancement method. (A) Short axis
slice demonstrating subendocardial infarction in the inferior wall (arrow). (B) Short axis slice demonstrating transmural
infarction in the inferior wall (arrow). (C) Two chamber view. Small subendocardial infarction in the basal slice of the inferior
wall is seen (arrow). (D) Two chamber view. Large transmural infarction in the anterior wall, the apex, and the apical segment
of the inferior wall is seen (arrow).
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This issue is a handicap of CMR. To make a decision about
performing PCI or CABG, precise information on coronary
artery anatomy is needed. In the case of multivessel disease,
the Syntax Score is recommended as a valuable tool in the
decision-making process for or against PCI or CABG in given
cases [2,16]. Despite technical developments made in the last
decade, CMR currently cannot be used in clinical practice for
visualisation of coronary arteries in case of CAD or the
assessment of the degree of stenosis [8,17]. Further progress is
needed in this ﬁeld.
Is there any additional disease that should be treated
simultaneously (valvular disease, dilated aorta)?
Simultaneously with stress testing for ischaemia, CMR
provides additional information on valvular status, aorta size,
left ventricular function and myocardial viability [8,17]. The
comprehensiveness and versatileness of CMR provide superi-
ority to other stress tests. Diagnosing aortic dilatation orsigniﬁcant valvular disease concomitant to newly diagnosed
stable CAD with a signiﬁcant extent of ischaemia, not only
determines the extensiveness of surgery (e.g. CABG alone vs
CABG plus valvular surgery), but also speaks for or against the
given method of treatment (conservative management vs PCI
vs CABG). All these information needs to be taken into
consideration.
If not CAD, what could be the cause of chest pain?
In some cases, CMR may be helpful in determining possible
causes of chest pain in patients in whom the study excluded
the presence of CAD. Hiatal hernia or spinal degenerative
disease is among the most common possible causes of chest
pain in patients without obstructive CAD.
Acute coronary syndromes
Contrary to stable CAD, invasive imaging is the ﬁrst step
in patients with myocardial infarction presenting with
c o r e t v a s a 5 7 ( 2 0 1 5 ) e 4 5 3 – e 4 6 1 e457ST-segment elevation and high risk patients with non-ST
elevation ACS [3,4]. The majority of crucial questions such as
those concerning the infarct related artery, the extent of
atherosclerosis in the remaining arteries, as well as the
immediate results of restoring ﬂow in the occluded artery areFig. 3 – Cardiac magnetic resonance in a patient with myocardit
suggestive of acute coronary syndrome. Diffuse subepicardial an
(LGE) are seen (arrows) in three chamber view (A), two chamber
Areas of LGE do not correspond to the coronary artery distributio
T2-weighted short axis image (E, arrow. The same slice as in (Dbased on invasive angiography. Nevertheless, management of
patients with ACS is not only limited to opening the occluded
artery (although this is crucial step for short-term and long-
term outcome). But what if no occluded artery is present and
troponin levels are high? Is it really ACS? Which is the culpritis admitted with chest pain and ST segment changes
d intramyocardial areas of late gadolinium enhancement
 view (B), 4 chamber view (C) and short axis basal slice (D).
n. Additionally, myocardial oedema is seen in pre-contrast
)).
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as a routine imaging modality in patients with ACS. However,
it provides useful and unique information inﬂuencing
patients' treatment and outcomes and should be considered
in selected patients [8,17]. Treating patients with ACS raises
the aforementioned questions and CMR helps to answer them.
Is it really ACS?
There is a small group of patients with suspected ACS in whom
a non-invasive imaging may be implemented. Performing CMR
in patients with acute chest pain without obstructive CAD on
invasive angiography demonstrated that myocarditis is the
most common ﬁnal diagnosis in this group of patients [18,19].
Differentiation of ischaemic aetiology (myocardial infarction –
MI) from non-ischaemic causes (such as myocarditis) as a
cause of troponin rise in patients with chest pain is based on
the localisation of LGE and myocardial oedema [8,17–19]. In the
case of MI, the localisation in subendocardial or transmural
and corresponds to the coronary artery supply territories
(Fig. 2). Myocarditis causes diffuse, patchy areas of LGE and
myocardial oedema with subepicardial, intramyocardial,
sometimes subendocardial localisation (Fig. 3).Fig. 4 – Cardiac magnetic resonance in acute myocardial infarct
as in two chamber view (A, B, arrows) consistent with the infa
T2-weighted imaging demonstrates myocardial oedema (large
the infarct (C, arrow).Which is the culprit artery?
The identiﬁcation of the culprit artery is usually straightfor-
ward on the basis of coronary angiography. In some patients,
however, coronary angiography reveals multivessel disease
with no obvious culprit lesion. Implementing CMR with LGE
imaging demonstrating infarct scar and T2-weighted imaging
that demonstrates myocardial oedema in the area supplied by
the infarct related artery may be useful in these cases (Fig. 4)
[20–23]. With this method, CMR has the ability to differentiate
patients with acute and chronic myocardial infarction. One
should note, that the progress of invasive imaging with the use
of optical coherence tomography in precise localisation of
culprit lesions should be recognised [24–26].
Are there any complications?
The vast majority of MI complications are diagnosed with the
use of echocardiography. However, CMR, additionally to the
assessment of location and the extent of MI, has the ability to
demonstrate various types of myocardial damage [27,28].
Although restoring ﬂow in coronary artery is the main aim of
treating MI, it does not necessarily reﬂect the restoration ofion. Subendocardial scar is seen both in short axis as well
rction in the area supplied by the right coronary artery.
r than the area of scar) consistent with the acute phase of
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shown to signiﬁcantly inﬂuence patients' prognosis and
therapeutic success [29]. With the use of CMR it is possible
to detect areas of irreversible microcirculation damage named
microvascular obstruction (MVO) (Fig. 5) [28]. Additionally,
myocardial haemorrhage may occur as the result of damage of
endothelial cells, loss of their structural integrity leading to
extravasation of blood cells in reperfused myocardium [28,30].
Finally, peri-infarct zone may be identiﬁed at the border
between scar tissue and viable myocardium and represents
arrhythmogenic substrate [31–33]. All these phenomena have
been shown to have negative prognostic implications
[28,32,33].
It has been shown that CMR is superior to echocardiogra-
phy in detecting intracavitary thrombi in the left ventricle inFig. 5 – Cardiac magnetic resonance in acute myocardial
infarction. Dark areas of microvascular obstruction inside
the infarct core are seen in a patient with large antero-
septal infarction (A, B, arrows). Additionally, thrombus in
the left ventricle is seen (B, asterisk).patients with recent MI [34–36]. This issue is of particular
importance since it requires antithrombotic treatment addi-
tional to antiplatelet therapy [4].
Contraindications to CMR and safety of the study
Prior to referring a patient for a CMR scan, a physician should
consider whether there are any contraindications to CMR.
Firstly, one should consider general contraindications for CMR
such as electronic devices (e.g. conventional pacemakers or
cardioverter-deﬁbrillators, insulin pumps), metallic foreign
bodies in the eyes and unknown implants [37]. Secondly,
speciﬁc contraindications to stress CMR should be listed [6,7]:
- adenosine, dipyridamole: 2nd or 3rd degree atrioventricular
block, sick sinus syndrome, chronic obstructive lung disease,
severe hypotension, unstable angina, decompensated heart
failure, allergy against vasodilator or contrast medium;
- regadenoson: 2nd or 3rd degree atrioventricular block, sinus
node dysfunction;
- dobutamine: severe hypertension (>220/120 mmHg), unsta-
ble angina, acute myocardial infarction, severe aortic
stenosis, hypertrophic obstructive cardiomyopathy, acute
perimyocarditis or endocarditis, glaucoma.
Additionally, the administration of gadolinium-chelate
contrast media is contraindicated in patients with severe
renal failure (glomerular ﬁltration rate <30 mL/min/1.73 m2).
On the other hand, it should be underlined that neither
coronary stents nor sternal suture wires are contraindications
to CMR.
Summary
The ﬁnal choice for stress testing for ischaemia should be
based on patient's suitability for a given test, availability, and
local expertise [1]. CMR is contraindicated in patients with
pacemakers or cardioverter-deﬁbrillators, stress echo is not a
preferred imaging technique in patients with poor acoustic
window, and SPECT – if radiation exposure should be avoided.
Thus, there is no ideal imaging modality for patients with CAD.
There are pros and cons to each of the methods. Providing
information on ventricular size and function, ischaemia and
viability, valvular function and aorta size, as well as aetiology
of left ventricular dysfunction (e.g. myocardial infarction vs
non-ischaemic causes such as myocarditis), CMR seems to be
close to the ideal imaging modality in coronary artery disease.
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